The Metastatic Brain Tumor Collaborative (MBTC), created by the American Brain Tumor Association (ABTA) announced $100,000 in ...

Researchers provide a comprehensive overview of the blood-brain barrier (BBB), detailing its cellular architecture, transport ...

Whole-brain radiotherapy was beneficial as consolidation, while temozolomide and etoposide were associated with decreased survival.

Genomic analysis revealed the XPO1 E571K mutation and others, including KLF2 and PI3KCD, were implicated in CNS involvement.

Chemotherapy, anti-cancer drugs that stop the growth of tumor cells, encompasses a wide variety of different agents.  Some ...

Financing led by Engine Ventures with support from Amplify Partners, Starbloom Capital, Connecticut Innovations, and E1 Ventures- Proceeds to accelerate strategic partnerships and internal CNS ...

Dr. Chamberlain is a leading medical oncologist with an extensive and distinct background in therapeutic development, clinical practice, and academic research with a focus in adult and pediatric ...

As part of the presentation Dr. Silberman will discuss the Company's drug candidate, TPI 287. TPI 287 is an abeotaxane and has the same mechanism of action as other taxanes, e.g. paclitaxel (Taxol®) ...

- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...

In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / ...